There are currently 1140 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
Recruiting
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
Gender:
All
Ages:
Between 6 years and 16 years
Trial Updated:
03/12/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hyperphosphatemia Related to Chronic Kidney Disease
ALTERRA Post-Approval Study
Recruiting
This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
Gender:
All
Ages:
All
Trial Updated:
03/12/2024
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
Recruiting
This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/11/2024
Locations: 304 - WellNow - Cincinnati, Cincinnati, Ohio
Conditions: COVID-19
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
Recruiting
The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: The Christ Hospital, Cincinnati, Ohio
Conditions: Heart Failure (for Example, Fluid Overload)
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
Recruiting
A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities. The investigators do not expect any adverse endocrine or metabolomic effects from the consumption of soy isoflavones.
Gender:
All
Ages:
Between 5 years and 12 years
Trial Updated:
03/10/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Non-Alcoholic Fatty Liver Disease
Donor-Derived Viral Specific T-cells (VSTs)
Recruiting
In this research study, the investigators want to learn more about the use of donor-derived viral specific T-cells (VSTs) to treat viral infections that occur after allogeneic stem cell transplant. A viral specific T cell is a T lymphocyte (a type of white blood cell) that kills cells that are infected (particularly with viruses). Allogeneic means the stem cells come from another person. These VSTs are cells specially designed to fight the virus infections that can happen after a bone marrow tra... Read More
Gender:
All
Ages:
4 weeks and above
Trial Updated:
03/09/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio +1 locations
Conditions: Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
Recruiting
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. There will also be secondary and exploratory objectives listed in the detailed description below.
Gender:
All
Ages:
22 years and below
Trial Updated:
03/08/2024
Locations: Cincinnati Children's Hospital Medical Center (Site 800), Cincinnati, Ohio
Conditions: NF1, Low-grade Glioma
Prospective SPINE Registry
Recruiting
This study is a prospective, multi-center, open label registry designed to collect real-world data on performance and safety data on RTI's spine products.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Lindner Center for Research & Education at The Christ Hospit, Cincinnati, Ohio
Conditions: Sacroiliac; Fusion, Sacroiliac, Joint Diseases, Musculoskeletal Diseases, Spinal Disease, Spinal Stenosis, Spinal Instability, Fusion of Joint, Fusion of Spine, Spinal Fusion, Spine
Intravesical BCG vs GEMDOCE in NMIBC
Recruiting
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach. The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high gr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio
Conditions: Non-muscle-invasive Bladder Cancer
A Study of BLB-201 RSV Vaccine in Infants and Children
Recruiting
This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10^6 PFU and 10^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 months of age) who may or may not have had prior respiratory syncytial virus (RSV) infection.
Gender:
All
Ages:
Between 8 months and 5 years
Trial Updated:
03/07/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Respiratory Syncytial Virus Infections
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
Recruiting
Uveitis is an inflammatory disease of the uvea, one of the highly vascularized fundamental structures of the eye. It is a rare condition in children, with an incidence in the pediatric population ranging from 2% to 14% of all uveitis cases. The diagnosis and management of patients with uveitis rely on a multidisciplinary approach involving an ophthalmologist, a rheumatologist, and an infectious disease specialist to establish the correct diagnosis and assess the involvement of other organs. In I... Read More
Gender:
All
Ages:
Between 1 year and 16 years
Trial Updated:
03/07/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Uveitis
A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101
Recruiting
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunct therapy with standard of care antibiotics. The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in healthy volunteers followed by a similar assessment in patients with suspected or confirmed community acquired bacterial pneumonia of moderate severity. The main questions the study aims to answer are: Are single ascending doses of a CMTX-101 intravenous (IV) infusion safe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Medpace Clinical Pharmacology Unit, Cincinnati, Ohio
Conditions: Community-acquired Pneumonia, Bacterial Pneumonia